These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19463381)

  • 1. Resisting the temptation to oversimplify antiplatelet resistance.
    Bhatt DL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):660-2. PubMed ID: 19463381
    [No Abstract]   [Full Text] [Related]  

  • 2. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Gurbel PA
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet function testing and implications for clinical practice.
    Collet JP; Montalescot G
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.
    Kereiakes DJ
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is heparin an acceptable anticoagulant when glycoprotein IIb/IIIa inhibitors are not used?
    Lee MS; Rha SW; Park KW; Kim MH
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):223-224. PubMed ID: 25616929
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiplatelet therapy and platelet function testing. Introduction.
    Braunwald E; Angiolillo D; Bates E; Berger PB; Bhatt D; Cannon CP; Furman MI; Gurbel P; Michelson AD; Peterson E; Wiviott S
    Clin Cardiol; 2008 Mar; 31(3 Suppl 1):I1. PubMed ID: 18481815
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiplatelet therapy and platelet function testing.
    Braunwald E; Angiolillo D; Bates E; Berger PB; Bhatt D; Cannon CP; Furman MI; Gurbel P; Michelson AD; Peterson E; Wiviott S
    Clin Cardiol; 2008 Mar; 31(3 Suppl 1):I36. PubMed ID: 18481821
    [No Abstract]   [Full Text] [Related]  

  • 9. Platelet activation and progression to complications.
    Kereiakes DJ; Michelson AD
    Rev Cardiovasc Med; 2006; 7(2):75-81. PubMed ID: 16915126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Konstantopoulos K; Mousa SA
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
    Mangiacapra F; Barbato E; Patti G; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2010 Mar; 3(3):318-23. PubMed ID: 20298992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets.
    Würtz M; Grove EL; Wulff LN; Kaltoft AK; Tilsted HH; Jensen LO; Hvas AM; Kristensen SD
    JACC Cardiovasc Interv; 2010 Aug; 3(8):828-35. PubMed ID: 20723855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing pharmacological strategies during PCI-analysis of a prematurely terminated trial.
    Kimmelstiel C
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1010-1. PubMed ID: 21598352
    [No Abstract]   [Full Text] [Related]  

  • 16. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
    Armstrong PC; Peter K
    Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral antiplatelet therapy in PCI patients.
    Sharma SK
    Catheter Cardiovasc Interv; 2010 Mar; 75 Suppl 1():S7-14. PubMed ID: 20333709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New directions in antiplatelet therapy.
    Ferreiro JL; Angiolillo DJ
    Circ Cardiovasc Interv; 2012 Jun; 5(3):433-45. PubMed ID: 22715450
    [No Abstract]   [Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy.
    Lippi G; Montagnana M; Danese E; Favaloro EJ; Franchini M
    Biomark Med; 2011 Feb; 5(1):63-70. PubMed ID: 21319966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study).
    Tamberella MR; Bhatt DL; Chew DP; Kereiakes DJ; Topol EJ; Steinhubl SR;
    Am J Cardiol; 2002 Jun; 89(12):1429-31. PubMed ID: 12062743
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.